Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00897325

Enrollment

811

Registered

2009-05-12

Start date

2006-09-25

Completion date

2019-12-31

Last updated

2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma

Brief summary

This research study is collecting and storing samples of bone marrow and blood from patients with relapsed acute lymphoblastic leukemia or relapsed non-Hodgkin lymphoma. Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and help predict the recurrence of cancer.

Detailed description

OBJECTIVES: I. Establish a mechanism to bank specimens of tumor cells and host germline DNA from patients with acute lymphoblastic leukemia (ALL) at first and subsequent relapse. II. Make these specimens available to qualified researchers to study the biology of ALL. OUTLINE: This is a multicenter study. Patients undergo collection of bone marrow and peripheral blood at diagnosis of relapse and/or at the end of the first month of treatment. Patients are followed periodically for up to 10 years.

Interventions

OTHERCytology Specimen Collection Procedure

Correlative studies

OTHERLaboratory Biomarker Analysis

Correlative studies

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 30 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of acute lymphoblastic leukemia (ALL) or prior history of non-Hodgkin lymphoma * In first or subsequent marrow relapse with ≥ 25% blasts in bone marrow and/or peripheral blood * Bone marrow and/or peripheral blood samples (≥ 5 mL) required at the time of diagnosis of relapse * No concurrent systemic antileukemic treatment administered for current relapse * Intrathecal chemotherapy allowed * On-therapy relapse allowed

Design outcomes

Primary

Measure	Time frame
Banking of tumor cells and germline DNA	Not Provided

Countries

Australia, Canada, Puerto Rico, Switzerland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026